Research programme:autoimmune and inflammatory disorders therapeutics - Cellestia Biotech
Latest Information Update: 27 Oct 2021
At a glance
- Originator Cellestia Biotech
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 12 Oct 2021 Preclinical trials in Autoimmune disorders in Switzerland (unspecified route) (Cellestia Biotech pipeline, October 2021)
- 12 Oct 2021 Preclinical trials in Inflammation in Switzerland (unspecified route) (Cellestia Biotech pipeline, October 2021)